According to a recent report from two faculty members at the Wake Forest University School a class of oral drugs for type 2 diabetes could have the potential to make heart failure worse. The report was published in Heart.
Sonal Singh (assistant professor of internal medicine) and Curt Furberg (professor of public health sciences) were reported as commenting: “We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market.”
Thiazolidinedione as a category includes Rosiglitazone and Pioglitazone. Singh and Furberg reportedly said: “At this time, justification for use of thiazolidinediones is very weak to non-existent.”
The drugs were tested in three trials called ACCORD, ADVANCE and the Veterans Affairs Diabetes study. Singh reportedly concluded: “Safer, cheaper and more effective treatment alternatives are available that do not carry these negative cardiovascular risks in patients with diabetes . The rationale for the use of the thiazolidinediones is unclear.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…